Sosa-Hernández Oscar, Sánchez-Cardoza Sofía
Epidemiología Hospitalaria, Hospital General de Zona 50, Instituto Mexicano del Seguro Social, San Luis Potosí, México.
Medicina de Rehabilitación, práctica privada, México.
Vacunas. 2022 May;23:68-70. doi: 10.1016/j.vacun.2022.02.002. Epub 2022 May 2.
Guillain-Barré syndrome (GBS) is a rare immune disorder that affects peripheral nerves and the cause is not known completely, but it is associated with infections by viruses or bacteria.
We report the case of a 23-year-old male patient, a health student, who start 24 hours after received the second dose of COVID-19 vaccine, with proximal weakness of the right upper limb, later on the left side with descending and distal progression.
GBS cases related to COVID-19 vaccines have been published, the most common being BNT162b2, which is mRNA, there are also cases published after the AZD1222 (ChAdOx1) vaccine, which is a non-replicating viral vector. The incidence of GBS is estimated at 0.43 per 100.00 doses applied, under registered national incidence of 1.1-1.8 per 100,000 persons per year.
It is important to mention that although GBS can occur after vaccination against COVID-19, this incidence is much lower than which occurs in the community in Mexico associated with other diseases, considering more common the presence of cases related to infectious gastrointestinal diseases.
吉兰 - 巴雷综合征（GBS）是一种罕见的影响周围神经的免疫性疾病，病因尚不完全清楚，但与病毒或细菌感染有关。
我们报告一例23岁男性患者，一名健康专业学生，在接种第二剂新冠疫苗24小时后发病，出现右上肢近端无力，随后左侧也出现症状，并呈下行性及远端进展。
与新冠疫苗相关的GBS病例已有报道，最常见的是mRNA疫苗BNT162b2引发的，也有接种非复制型病毒载体疫苗AZD1222（ChAdOx1）后出现GBS病例的报道。GBS的发生率估计为每接种100,000剂出现0.43例，低于墨西哥全国每年每10万人中1.1 - 1.8例的发病率。
需要指出的是，尽管接种新冠疫苗后可能发生GBS，但与墨西哥社区中与其他疾病相关的发病率相比，这一发病率要低得多，因为与感染性胃肠疾病相关的病例更为常见。
